Prospective, Randomized, Multi-center Clinical Study of Plasma Disc Decompression (SPINE)

August 25, 2015 updated by: ArthroCare Corporation

Prospective, Randomized, Multi-center Clinical Study of Plasma Disc Decompression Efficacy

The goal of this post-marketing surveillance study is to compare two procedures which are used to treat patients who require a disc decompression procedure. These procedures are: 1) plasma disc decompression procedure using Coblation technology and 2) fluoroscopy guided transforaminal epidural steroid injection (TFESI). The study will evaluate treatment efficacy and rate of improvement in symptoms through the first six months following the procedure.

The principal objectives of this study are to determine whether subjects receiving the plasma disc decompression procedure demonstrate:

  1. Improved clinical outcomes over subjects receiving TFESI
  2. More rapid reversal of symptoms than subjects receiving TFESI

Study Overview

Detailed Description

Chronic leg and back pain are two of the most common ailments in our society, and are associated with serious financial and social consequences. One surgical treatment modality is plasma disc decompression, based on the principle that inducing a small reduction of volume in the closed hydraulic space of an intact (contained herniated) disc can relieve pressure, and thereby reduce or eliminate pain. Another widely accepted treatment is transforaminal epidural steroid injection (TFESI), which delivers a high concentration of corticosteroid to the targeted disc nerve interface, and is thought to decrease pain by reducing inflammation.

This study proposes to compare the efficacy of the plasma disc decompression procedure to the standard TFESI series in patients who have failed to improve after an initial TFESI injection. The goal is to better understand the differences between these two treatment modalities and to monitor the rates of symptom improvement through the first six months between patients receiving a series of at least two selective nerve root injections and those undergoing the one-time plasma disc decompression procedure after failing one fluoroscopy guided TFESI. Patients will continue to be monitored over the 2-year post-procedure period to assess stability of treatment effect.

Study Type

Interventional

Enrollment (Actual)

90

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Arizona
      • Scottsdale, Arizona, United States, 85260
        • The Orthopedic Clinic Association
    • Arkansas
      • Little Rock, Arkansas, United States, 72205
        • Innovative Spine Care
    • California
      • Napa, California, United States, 94558
        • SpectrumCare Rehabilitation Medical Center Inc.
    • Colorado
      • Thornton, Colorado, United States, 80229
        • North Valley Rehabilitation Hospital
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Beth Israel Deaconess Medical Center, Arnold Pain Management Center,
    • Michigan
      • Ann Arbor, Michigan, United States, 48108
        • The University of Michigan, The Spine Program
    • Minnesota
      • Edina, Minnesota, United States, 55435
        • Medical Advanced Pain Specialists (MAPS)
      • Minneapolis, Minnesota, United States, 55431
        • TRIA Orthropaedic Center
    • North Carolina
      • Charlotte, North Carolina, United States, 28203
        • OrthoCarolina
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15224
        • Western Pennsylvania Hospital
      • Pittsburgh, Pennsylvania, United States, 15213-2582
        • University of Pittsburgh Medical Center (UPMC) Presbyterian
    • Texas
      • San Antonio, Texas, United States, 78209
        • Consultants in Pain Research
    • Vermont
      • Burlington, Vermont, United States, 05401
        • University of Vermont College of Medicine, Center for Pain Mgmt

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patient has one symptomatic contained, focal herniated lumbar disc.
  2. Patient's age should be at least 18 years old and no more than 75 years old.
  3. Selective nerve root injection or epidural steroid injection for symptomatic herniated disc, received between 3 weeks and six months ago.
  4. A VAS score for radicular pain of 50 or greater on a scale of 0 to 100.
  5. Radicular pain concordant with image findings (MRI or CT).
  6. Disc height greater than 50%.
  7. Patient signs informed consent.

Exclusion Criteria:

  1. Patient is pregnant, or pregnancy is suspected or planned within the study timeframe.
  2. Patient is receiving Worker's compensation or is in litigation related to back/leg pain.
  3. Patient has a cardiac pacemaker, automatic defibrillator, or any peripheral stimulator leads in the lumbar area.
  4. Allergy to contrast media or drugs to be used in the intended procedure.
  5. Medical co-morbidities that preclude surgical intervention.
  6. Patient is receiving anti-psychotic therapy.
  7. Patient is a prisoner.
  8. Patient is incapable of understanding or responding to the study questionnaires.
  9. History of previous spinal surgery at, or directly adjacent to, the level to be treated.
  10. Patient is morbidly obese (BMI ≥ 40).
  11. Patient is simultaneously participating in another device or drug study related to limb/axial pain.
  12. Patient has a spinal fracture, tumor or infection.
  13. Radicular pain originating from more than one disc level.
  14. Axial (back) pain greater than radicular (leg) pain.
  15. Clinical evidence of cauda equina syndrome.
  16. Progressive neurologic deficit.
  17. Radiological evidence of spondylolisthesis at the level to be treated.
  18. Radiological evidence of moderate/severe stenosis at the level to be treated.
  19. Evidence of extruded or sequestered disc herniation on magnetic resonance imaging.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: 1
Fluoroscopy guided transforaminal epidural steroid injection (TFESI)
Injection of steroid solution into the lumbar level
Other Names:
  • TFESI
Experimental: 2
Percutaneous Disc Decompression of the lumbar level which is secondary to radicular pain
Device technique will be used per IFU
Other Names:
  • Percutaneous Disc Decompression

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Pain status change assessed using a visual analogue scale (VAS) for radicular pain intensity.
Time Frame: 6 weeks, 3 mos., 6 mos., 1 year, 2 years
6 weeks, 3 mos., 6 mos., 1 year, 2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Functional status change evaluated using the Oswestry Disability Questionnaire.
Time Frame: 6 weeks, 3 mos., 6 mos., 1 year, 2 years
6 weeks, 3 mos., 6 mos., 1 year, 2 years
General health status change determined using the SF-36.
Time Frame: 6 weeks, 3 mos., 6 mos., 1 year, 2 years
6 weeks, 3 mos., 6 mos., 1 year, 2 years
Employment status change examined using a questionnaire developed by the American Academy of Orthopaedic Surgeons (AAOS) and the North American Spine Society (NASS).
Time Frame: 6 weeks, 3 mos., 6 mos., 1 year, 2 years
6 weeks, 3 mos., 6 mos., 1 year, 2 years
Subject global satisfaction post-procedure assessed using a global satisfaction statement.
Time Frame: 6 weeks, 3 mos., 6 mos., 1 year, 2 years
6 weeks, 3 mos., 6 mos., 1 year, 2 years
Change in frequency and type of pain medication use.
Time Frame: 6 weeks, 3 mos., 6 mos., 1 year, 2 years
6 weeks, 3 mos., 6 mos., 1 year, 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Peter Gerzten, MD, Univ. of Pittsburgh Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2004

Primary Completion (Actual)

December 1, 2007

Study Completion (Actual)

April 1, 2009

Study Registration Dates

First Submitted

September 13, 2005

First Submitted That Met QC Criteria

September 13, 2005

First Posted (Estimate)

September 19, 2005

Study Record Updates

Last Update Posted (Estimate)

August 26, 2015

Last Update Submitted That Met QC Criteria

August 25, 2015

Last Verified

August 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Radicular Pain

Clinical Trials on Fluoroscopy guided transforaminal epidural steroid injection (TFESI)

3
Subscribe